Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Legacy Wealth Asset Management LLC

Legacy Wealth Asset Management LLC lifted its stake in Edwards Lifesciences Co. (NYSE:EW) by 2.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,410 shares of the medical research company’s stock after purchasing an additional 452 shares during the period. Legacy Wealth Asset Management LLC’s holdings in Edwards Lifesciences were worth $1,664,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. DSM Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth $28,000. Turtle Creek Wealth Advisors LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $34,000. Riverview Trust Co acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth about $34,000. Pingora Partners LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $38,000. Finally, SRS Capital Advisors Inc. raised its position in shares of Edwards Lifesciences by 292.6% during the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after acquiring an additional 474 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of NYSE:EW traded down $0.15 on Thursday, reaching $91.08. 1,497,118 shares of the company were exchanged, compared to its average volume of 3,054,446. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The company has a 50-day moving average of $88.04 and a 200-day moving average of $85.60. The firm has a market cap of $54.88 billion, a price-to-earnings ratio of 39.26, a price-to-earnings-growth ratio of 3.34 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Equities analysts forecast that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Stifel Nicolaus increased their price target on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Friday, April 26th. Piper Sandler increased their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday, April 26th. StockNews.com raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Thursday, June 27th. Evercore ISI upped their price objective on shares of Edwards Lifesciences from $89.00 to $91.00 and gave the company an “in-line” rating in a research note on Tuesday. Finally, Wells Fargo & Company lifted their target price on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a research report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $95.18.

Insider Buying and Selling

In other Edwards Lifesciences news, CEO Bernard J. Zovighian acquired 580 shares of the stock in a transaction that occurred on Monday, May 6th. The shares were purchased at an average cost of $85.74 per share, with a total value of $49,729.20. Following the purchase, the chief executive officer now owns 3,268 shares in the company, valued at $280,198.32. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Bernard J. Zovighian bought 580 shares of the stock in a transaction on Monday, May 6th. The shares were purchased at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now owns 3,268 shares in the company, valued at $280,198.32. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,499 shares of company stock valued at $7,866,511. 1.27% of the stock is owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.